BioSphere Medical Schedules Fourth Quarter 2009 Financial Results Conference Call February 11

BioSphere Medical, Inc. (NASDAQ: BSMD), the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that it plans to issue its financial results for the fourth quarter ended December 31, 2009 on February 10 after the close of the stock market. Management will conduct a conference call on Thursday, February 11 at 8:30 a.m. Eastern time to discuss these results.

The number to dial is 1-888-563-6275 (US/Canada) or 1-706-643-3137 (International), and the conference ID is 53823025. Please call approximately ten minutes before the call is scheduled to begin. The live webcast will be available at the "Investors" section of BioSphere Medical’s Web site at www.biospheremed.com. A replay of the webcast will also be available on BioSphere Medical’s Web site.

About BioSphere Medical, Inc.

BioSphere Medical, Inc. seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the use of its products for the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments.

Biosphere Medical (MM) (NASDAQ:BSMD)
過去株価チャート
から 9 2024 まで 10 2024